IP Library Granted Patent US 6,838,284
Granted Patent B2
US 6,838,284 · App. 10/178,050 · Granted Jan 4, 2005

Cell culture medium containing growth factors and L-glutamine

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,838,284
App. No.
10/178,050
Granted
Jan 4, 2005
Kind
B2
Abstract

The invention relates to a culture medium for culturing cells, in particular human cells in a process for tissue engineering bone. The medium comprises glucose, a mineral, a vitamin, a growth factor and L-glutamine, wherein the L-glutamine is present in a concentration of at least 300 mg/L.

Claims (23)

1. Culture medium comprising glucose, a mineral, a vitamin, a growth factor and L-glutamine, wherein the L-glutamine is present in a concentration of at least 300 mg/L and wherein the vitamin is L-ascorbic acid in an amount between 75 and 1500 mg/L.

2. Culture medium according to claim 1 , wherein the L-glutamine is present in a concentration between 400 and 800 mg/L.

3. Culture medium according to claim wherein L-ascorbic acid is added in the form of L-ascorbic acid-2-phosphate.

4. Culture medium according to claim 1 , wherein the growth factor is chosen from the group of bone morphogenetic protein, epidermal growth factor, basic fibroblast growth factor, nerve growth factor, bone derived growth factor, transforming growth factor-β1, and human growth hormone.

5. Culture medium according to claim 4 , wherein the factor is basic fibroblast growth factor.

6. Culture medium according to claim 5 , wherein the basic fibroblast growth factor is present in a concentration between 0.1 and 10 μg/L.

7. Culture medium according to claim 1 , wherein the mineral comprises one or more ions chosen from the group of calcium, potassium, lithium, magnesium, sodium, sulfate, chloride, bicarbonate, and dihydrogenphosphate ions.

8. Culture medium according to claim 7 , wherein the mineral is present in a concentration between 5 and 15 g/L.

9. Culture medium according to claim 1 , further comprising a vitamin chosen from the group consisting of biotin, D-calcium pantothenate, choline chloride, folic acid, i-inositol, nicotinamide, pyridoxal, riboflavin, thiamine vitamin B 12 , vitamin A and combinations thereof.

10. Culture medium according to claim 1 comprising one or more amino acids chosen from the group of L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-cysteine, L-cysteine, L-glutamic acid, L-alanyl-L-glutamine, glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, and L-valine.

11. Culture medium according to claim 10 , wherein the amino acids are present in a concentration between 0.8 and 5 g/L.

12. Culture medium according to claim 1 , comprising an antibiotic.

13. Culture medium according to claim 12 , wherein the antibiotic is chosen from the group of penicillin G, gentamicin, fungizone, and streptomycin.

14. Culture medium according to claim 13 comprising as antibiotic a combination of penicillin G and streptomycin, wherein both penicillin G and streptomycin are present in an amount of 50-150 μg/mL.

15. Culture medium according to claim 1 comprising dexamethasone.

16. Culture medium according to claim 1 comprising distilled water.

17. Culture medium according to claim 1 comprising a ribonucleoside and/or a deoxyribonucleoside.

18. Culture medium according to claim 1 further comprising serum.

19. Use of a culture medium according to claim 1 for culturing human cells, comprising the steps of:

obtaining human cells; and

culturing the human cells in the culture medium of claim 1 .

20. Use according to claim 19 , wherein the cells are chosen from the group of stem cells, progenitor cells, mesenchymal cells, epithelial cells, cartilaginous cells, osseous cells, muscular cells, gland cells, fat cells, pericytes, satellite cells and dermal cells.

21. Use according to claim 20 , wherein the cells are progenitor cells.

Assignments (5)
TERMINATION OF SECURITY INTEREST Recorded Oct 14, 2008
From: BIOLEX THERAPEUTICS, INC.
To: OCTOPLUS SCIENCES B.V.; CHIENNA B.V.; OCTOPLUS DEVELOPMENT B.V.; OCTOPLUS TECHNOLOGIES B.V.
Reel/Frame 021701/0168 →
SECURITY AGREEMENT Recorded Jul 15, 2008
From: OCTOPLUS SCIENCES B.V.; CHIENNA B.V.; OCTOPLUS DEVELOPMENT B.V.; OCTOPLUS TECHNOLOGIES B.V.
To: BIOLEX THERAPEUTICS, INC.
Reel/Frame 021230/0881 →
SECURITY AGREEMENT Recorded May 30, 2008
From: OCTOPLUS SCIENCES B.V.; CHIENNA B.V.; OCTOPLUS DEVELOPMENT B.V.; OCTOPLUS TECHNOLOGIES B.V.
To: LSP III OMNI INVESTMENT COOPERATIEF U.A.; S.R. ONE, LIMITED
Reel/Frame 021018/0559 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2008
From: ISOTIS N.V.
To: OCTOPLUS SCIENCES B.V.
Reel/Frame 020540/0095 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2002
From: DE BRUIJN, JOOST DICK; TIBBE, GERHARDUS JOHANNES MARIA; DA SILVA MADUREIRA MENDES, SANDRA CLAUDIA
To: ISO TIS N.V.
Reel/Frame 013267/0279 →